CSL’s undoubtedly a quality business but it simply got ahead of itself from a valuation perspective in 2019 / 2020 however after falling ~30% in a rising market we believe some value has been restored, especially if the upside drive by the $A does abate as we anticipate in H2 of 2021. MM is considering accumulating the blood plasma stock around $250 while leaving some ammunition to average at lower levels.
MM likes CSL around $240-$250.
Add To Hit List
